Why does splanchnic vasodilation occur in cirrhosis?

Why Splanchnic Vasodilation Occurs in Cirrhosis

Splanchnic vasodilation in cirrhosis is triggered by portal hypertension and results from a combination of increased production of endogenous vasodilators (particularly nitric oxide), decreased vascular responsiveness to vasoconstrictors, and chronic systemic inflammation driven by bacterial translocation from the gut. 1, 2

Primary Pathophysiological Mechanisms

Portal Hypertension as the Initiating Trigger

• Portal hypertension is the essential prerequisite for splanchnic vasodilation to develop, as arterial vasodilation in the splanchnic circulation is directly triggered by elevated portal pressure 1, 2
• The increased intrahepatic vascular resistance (70% structural from fibrosis and nodules, 30% functional from vasoconstriction) creates the portal hypertension that initiates this cascade 3

Vasodilator Overproduction

• Nitric oxide (NO) plays the most crucial role among all vasodilators in mediating splanchnic vasodilation 4, 5
• Enhanced endothelial nitric oxide synthase (eNOS) and inducible NOS (iNOS) expression occurs specifically in mesenteric arteries of cirrhotic patients, driving increased NO production 6, 4
• Additional vasodilators contributing to the phenomenon include prostacyclin, carbon monoxide, epoxyeicosatrienoic acids, glucagon, endogenous cannabinoids, and adrenomedullin 4, 5
• The renin-angiotensin system paradoxically contributes through increased ACE2 activity, which converts angiotensin II to angiotensin-(1-7), activating the MAS receptor and causing splanchnic vasodilation 7

Bacterial Translocation and Systemic Inflammation

• Chronic inflammation from bacterial translocation is a primary driver of the vasodilatory state, not merely a consequence 1
• Pathogen-associated molecular patterns (PAMPs) from gut bacteria and danger-associated molecular patterns (DAMPs) from the diseased liver activate immune cells 1
• These activated immune cells produce pro-inflammatory cytokines, chemokines, and reactive oxygen/nitrogen species that directly enhance endothelial vasodilator production 1
• Changes in the intestinal microbiome and increased intestinal permeability facilitate this bacterial translocation 1

Vascular Hyporesponsiveness to Vasoconstrictors

• Splanchnic vessels in cirrhosis demonstrate decreased contractile responses to vasoconstrictors like phenylephrine, independent of increased vasodilator production 6, 5
• This hyporesponsiveness affects both splenic and mesenteric arterial beds, though through different mechanisms 6
• In mesenteric arteries, both increased vasodilator response and decreased vasoconstrictor response contribute, while in splenic arteries, decreased vasoconstrictor response predominates 6

Clinical Consequences of Splanchnic Vasodilation

Effective Arterial Underfilling

• The vasodilation creates "effective arterial underfilling" rather than true hypovolemia—patients are actually hypervolemic but have inadequate effective circulating volume 1, 2
• This paradoxical state occurs because blood pools in the dilated splanchnic circulation, reducing effective arterial blood volume despite total body fluid overload 8

Compensatory Neurohumoral Activation

• The perceived hypovolemia triggers activation of the renin-angiotensin-aldosterone system, sympathetic nervous system, and arginine-vasopressin secretion 1
• These compensatory mechanisms cause renal vasoconstriction and sodium/water retention, leading to ascites formation 1
• This represents the central pathophysiological event linking portal hypertension to all major complications of decompensated cirrhosis 1

Progression to Multi-Organ Dysfunction

• Splanchnic vasodilation directly contributes to hepatorenal syndrome development through renal hypoperfusion 1, 2
• The vasodilation increases susceptibility to shock states, particularly when bacterial infection adds additional vasodilatory stress 1, 2
• Cirrhotic cardiomyopathy compounds the problem by preventing adequate cardiac output increases to compensate for the vasodilation 1, 2

Important Clinical Caveats

• The phenomenon is multifactorial—no single mediator is solely responsible, making targeted therapy challenging 4, 5
• Splanchnic vasodilation occurs nearly universally in decompensated cirrhosis with portal hypertension, indicating advanced disease 2
• The extent of vasodilation correlates with disease severity and predicts complications including hepatorenal syndrome, which develops in over 50% of outpatients with decompensated cirrhosis 2
• Mean arterial pressure should be maintained >65 mmHg to ensure adequate splanchnic organ perfusion, as autoregulation is compromised 2
• Beta-blockers must be used cautiously in patients with refractory ascites, as excessive cardiac output reduction can worsen the effective hypovolemia 2